Hairy Cell Leukemia
A rare, slow-growing blood cancer where B-cells develop 'hairy' projections, causing an enlarged spleen and low blood counts, highly curable with specific chemotherapy.
Emergency Management: Spontaneous splenic rupture from massive splenomegaly, presenting as acute abdominal pain and hemorrhagic shock.
Hairy cell leukemia (HCL) is a rare, slow-growing, chronic B-cell malignancy characterized by the accumulation of abnormal B lymphocytes with distinct hair-like cytoplasmic projections. These cells infiltrate the bone marrow, spleen, and rarely the liver, leading to profound pancytopenia and massive splenomegaly.
Detailed Overview
HCL accounts for about 2% of all leukemias. It is fundamentally driven by the BRAF V600E mutation, which is present in virtually all classic cases. The disease is notable for causing marrow fibrosis ('dry tap' on aspiration) and severe monocytopenia, rendering patients highly susceptible to atypical infections (like MAC and opportunistic fungi). Despite its malignant nature, HCL is highly treatable, and a single course of purine analog chemotherapy can induce remissions lasting over a decade, giving patients a near-normal life expectancy.
Epidemiology & Demographics
Incidence is roughly 0.3 cases per 100,000 per year. It strongly favors males (M:F ratio 4:1 to 5:1) and primarily affects older adults, with a median age at diagnosis of 55 years.
Etiological Mechanism
The activating somatic mutation BRAF V600E (a substitution of glutamic acid for valine at amino acid 600) is the genetic hallmark, leading to constitutive activation of the RAF-MEK-ERK signaling pathway, which promotes survival and proliferation of the malignant B-cells.
Primary Causes
["Acquired BRAF V600E mutation in a mature B-lymphocyte."]
The mutated B-cells proliferate slowly but steadily. They accumulate in the bone marrow and spleen. In the marrow, the neoplastic cells induce reticulin fibrosis (via secretion of FGF and TGF-beta), which chokes out normal hematopoiesis, leading to pancytopenia (anemia, neutropenia, thrombocytopenia, and notably, severe monocytopenia). In the spleen, they accumulate in the red pulp (unlike other lymphomas which involve the white pulp), causing massive splenomegaly which further worsens cytopenias via hypersplenism.
Diagnostic Criteria & Guidelines
Diagnosis based on morphology (hairy cells in blood/marrow), specific flow cytometry immunophenotype (positive for CD11c, CD25, CD103, and CD123), and presence of the BRAF V600E mutation.
Asymptomatic patients are observed. Symptomatic patients receive a single course of a purine analog: Cladribine (0.1 mg/kg/day via continuous IV infusion for 7 days) OR Pentostatin (4 mg/m2 IV every 2 weeks until maximum response). These agents achieve complete remission rates of 75-90%.
Second-Line & Adjunctive Therapy
For relapsed or refractory disease, treatment options include repeating the purine analog (if relapse is > 2 years), combining Cladribine with Rituximab (anti-CD20), or using targeted therapy with a BRAF inhibitor like Vemurafenib (960 mg PO BID) or Moxetumomab pasudotox (anti-CD22 immunotoxin).
Surgical & Procedural Management
Splenectomy is rarely performed today, but historically was the primary treatment. It may be used for massive, painful splenomegaly refractory to chemotherapy, or bleeding spleen.
Patient Counseling & Advice
Inform the patient that while it is a leukemia, it is extremely slow-growing and highly treatable. Warn about the severe, prolonged immunosuppression caused by Cladribine, necessitating prompt reporting of any fever.
Follow-Up & Monitoring Schedule
CBC and physical exam every 3-6 months. Eradication of minimal residual disease (MRD) is monitored via bone marrow flow cytometry, though patients can have long remissions even with MRD.
Preventive Strategies
Prophylaxis against opportunistic infections (e.g., TMP-SMX for PCP, Acyclovir for VZV) is often initiated during and after purine analog therapy until CD4 counts recover.
Excellent. Overall survival is virtually identical to that of the age-matched general population. Relapses can occur (often 5-10 years post-treatment) but are usually highly responsive to re-treatment.